Clinical Trials Directory

Trials / Completed

CompletedNCT00003935

Combination Chemotherapy Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma

Treatment of Children With Diffuse Intrinsic Brain Stem Glioma With Standard Dose Irradiation and Vincristine Plus Oral VP-16, A POG Pilot Study

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
31 (actual)
Sponsor
Children's Oncology Group · Network
Sex
All
Age
3 Years – 21 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one drug with radiation therapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of vincristine plus etoposide and radiation therapy in treating children who have newly diagnosed brain stem glioma.

Detailed description

OBJECTIVES: I. Evaluate the efficacy of vincristine plus etoposide with concurrent radiotherapy on one year survival in children with newly diagnosed diffuse intrinsic brain stem glioma. II. Assess the toxicity of this regimen in this patient population. OUTLINE: Induction: Patients receive oral etoposide daily on days 1-21 and vincristine IV on days 1, 8, and 15. Treatment repeats every 4 weeks for 2 courses. Patients receive radiotherapy daily for 6 weeks concurrently with induction chemotherapy. Maintenance: One week after induction therapy, patients receive vincristine IV on days 1 and 8 and oral etoposide daily on days 1-21. Treatment repeats every 4 weeks for 10 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study within 2 years.

Conditions

Interventions

TypeNameDescription
DRUGetoposide
DRUGvincristine sulfate
RADIATIONradiation therapy

Timeline

Start date
1999-09-01
Primary completion
2003-10-01
Completion
2007-03-01
First posted
2004-02-20
Last updated
2014-07-28

Locations

110 sites across 6 countries: United States, Australia, Canada, Netherlands, Puerto Rico, Switzerland

Source: ClinicalTrials.gov record NCT00003935. Inclusion in this directory is not an endorsement.